Read more from the original source:
Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh